XIENCE Implantation Followed By Short Dual Antiplatelet Therapy: 'The New Normal'?

Niels Mr van der Sangen; Wouter J Kikkert; José Ps Henriques; Bimmer Epm Claessen

doi:10.17925/HI.2021.15.2.65

XIENCE Implantation Followed By Short Dual Antiplatelet Therapy: 'The New Normal'?

Heart Int. 2021 Dec 10;15(2):65-66. doi: 10.17925/HI.2021.15.2.65. eCollection 2021.

Authors

Niels Mr van der Sangen¹, Wouter J Kikkert^{1

2}, José Ps Henriques¹, Bimmer Epm Claessen¹

Affiliations

¹ Department of Cardiology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
² Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.

Abstract

The XIENCE family of everolimus-eluting stents ranks among the most used and most widely studied drug-eluting stents worldwide. In patients at high bleeding risk undergoing non-complex percutaneous coronary intervention with these stents, a shortened dual antiplatelet therapy (DAPT) regimen of 1-3 months appears to be associated with a reduced rate of major bleeding, a similar rate of ischaemic events and a very low incidence of stent thrombosis after DAPT discontinuation compared with DAPT up to 12 months.

Keywords: P2Y12 inhibitor; XIENCE stent; aspirin; drug-eluting stents; dual anti-platelet therapy; high bleeding risk; percutaneous coronary intervention.

Publication types

Editorial

Grants and funding

Support: No funding was received in the publication of this article.